Prostate News and Research

RSS

Mylan receives tentative FDA approval for generic versions of Benicar and Uroxatral

Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg.

22 Oct 2008

Chance of dying from cancer before the age of 84 is falling

The chance of dying from cancer before the age of 84 is becoming much smaller for most types of cancer and should continue falling over the next 20 years according to a new study from Cancer Research UK.

19 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Weight linked to prostate cancer death

New research, funded in part by the Canadian Cancer Society, shows that men suffering from prostate cancer are up to 2 1/2 times more at risk of dying from the disease if they are overweight or obese. The men who participated in the study had been weighed prior to being diagnosed with prostate cancer.

5 Oct 2008

New advance in robotic prostate surgery

To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.

2 Oct 2008

Raised risk of prostate cancer in Black men

Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.

2 Oct 2008

New technology promises tests for diseases such as cancer in 15 minutes

Scientists at Leeds University in the UK say soon, testing for diseases such as cancer and multiple sclerosis, could take as little as 15 minutes and could be as simple as using a pregnancy testing kit.

1 Oct 2008

Gap in black, white new cancer diagnoses narrowing in Missouri; mortality rate gap falling more slowly, study finds

The gap between blacks and whites in Missouri for newly diagnosed cancers is narrowing in part because of an overall decline in smoking and an increase in cancer screenings, according to a study to be published early next year in the journal Missouri Medicine, the AP/St. Louis Post-Dispatch reports.

29 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Prostate cancer genes behave like those in embryo

Gene activity in prostate cancer is reminiscent of that in the developing fetal prostate, providing further evidence that all cancers are not equal, Johns Hopkins researchers report. The finding could help scientists investigate how to manipulate the genetic program to fight a disease whose biology remains poorly understood despite more than half a century of investigation.

16 Sep 2008

Novel treatment for prostate cancer

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.

15 Sep 2008

Trabectedin shows promise for ovarian cancer

Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.

15 Sep 2008

An 'HIV-test' equivalent for early detection of lung cancer

A team of researchers led by Fred Hutchinson Cancer Research Center reports online today in the Journal of Clinical Oncology the validation of a potential "HIV-test" equivalent for the early detection of lung cancer. The test, which relies on immune-system signals, much like an HIV test, can detect the presence of lung cancer a year prior to diagnosis, long before symptoms appear.

15 Sep 2008

Lung cancer in non-smokers is sixth biggest cancer killer

While lung cancer in smokers and former smokers is the biggest cancer killer by far, lung cancer in people who have never smoked is -- by itself -- the sixth biggest cancer killer in the United States.

15 Sep 2008

More prostate cancer but fewer deaths

A major study by researchers from the Cancer Council Australia has found that even though more men are being diagnosed with prostate cancer, fewer are dying from the disease.

15 Sep 2008

Scientists discover common variants in the human genome conferring risk of bladder cancer

Scientists at deCODE genetics and colleagues at Radboud University Medical Center in the Netherlands today report the discovery of two common single-letter variants in the human genome (SNPs) that confer increased risk of urinary bladder cancer.

14 Sep 2008

Anti-inflammatory drugs may mask prostate cancer marker

Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications.

14 Sep 2008

BioServe introduces customizable DNA panels for genetic research

BioServe has announced a more affordable pricing plan for its vast bank of DNA with comprehensive, de-identified, covariate data that includes age, gender, diet, body mass index (BMI), and race. In addition, each sample has data on the complete diagnostic and treatment history of the donor.

14 Sep 2008